About Augmenix
Augmenix is a company based in Waltham (United States) founded in 2008 was acquired by Boston Scientific in September 2018. Augmenix has raised $46.6 million across 7 funding rounds from investors including Boston Scientific, Varian and Pinnacle Ventures. The company has 153 employees as of December 31, 2018. Augmenix operates in a competitive market with competitors including AmacaThera, Regentis Biomaterials, LifeSprout, Biosyntech and ECM Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 153 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Augmenix, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$46.6 M (USD)
in 7 rounds
-
Latest Funding Round
$6 M (USD), Series E
Jul 18, 2016
-
Investors
Boston Scientific
& 7 more
-
Employee Count
153
as on Dec 31, 2018
-
Acquired by
Boston Scientific
(Sep 06, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Augmenix
Augmenix has successfully raised a total of $46.6M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $6 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Augmenix
Augmenix has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, Varian and Pinnacle Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Late stage tech-focused VC firm funding companies in the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked |
Investor details for Augmenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Augmenix
Investment portfolio details for Augmenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Augmenix
Detailed financials for Augmenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Augmenix Comparisons
Peer comparison for Augmenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Augmenix
Augmenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AmacaThera, Regentis Biomaterials, LifeSprout, Biosyntech and ECM Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Injectable hydrogel platform developed for therapeutic medical applications.
|
|
| Locked | Locked | Locked |
Regentis Biomaterials is focused on tissue repair hydrogel technology.
|
|
| Locked | Locked | Locked |
Synthetic soft tissue substitutes for cosmetics and reconstructive surgery
|
|
| Locked | Locked | Locked |
Biotherapeutic thermogels are developed for tissue repair applications.
|
|
| Locked | Locked | Locked |
Diagnostic and therapeutic products from extracellular matrix are developed.
|
Detailed competitors of Augmenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Augmenix
Complete news archive for Augmenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Augmenix
Augmenix was founded in 2008.
Augmenix is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Augmenix is a funded company, having raised a total of $46.6M across 7 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Augmenix is 153.
Provider of a hydrogel spacer for prostate cancer radiation therapy. This hydrogel is injected to create space between the rectum and prostate, reducing radiation exposure to the rectum during treatment. The procedure aims to minimize urinary, sexual, and bowel side effects associated with radiation therapy. The hydrogel is made of polyethylene glycol (PEG) and is intended for temporary use during radiotherapy. Potential complications, though rare, include injection site pain, inflammation, and other issues. Patients should discuss risks and benefits with their physician before treatment.
Augmenix's top competitors include AmacaThera, LifeSprout and Regentis Biomaterials.
Augmenix has 8 investors. Key investors include Boston Scientific, Varian, Pinnacle Ventures, Excelestar Ventures, and Catalyst Health Ventures.